Key result
Type 2 diabetes in rats drives compensatory ATP production, worsening mitochondrial dysfunction via reactive oxygen species.
Why the study?
Diabetic cardiomyopathy is a leading cause of mortality in diabetes, but the exact reasons why diabetes triggers mitochondrial dysfunction and oxidative stress remain unclear.
Multi-omics analysis of ZDF rat hearts reveals that diabetic cardiomyopathy is driven by mitochondrial dysfunction, elevated oxidative stress, and accelerated AMP degradation via xanthine oxidoreductase.
Animal metabolic findings in diabetes warrant no clinical practice change; leaves open human translation and therapeutic targeting.
Diabetic cardiomyopathy (DCM) is a leading cause of mortality in patients with diabetes, highlighting the need to better understand its mechanisms for effective treatment. The primary pathogenic mechanism of DCM is mitochondrial dysfunction associated with increased oxidative stress; however, the exact reasons why diabetes triggers this condition remain unclear. An 8-week-old male Zucker diabetic fatty rat model of type 2 diabetes was used for this analysis. Metabolomic and lipidomic analyses were conducted not only in the heart but also across several other organs to elucidate metabolic changes specifically occurring in the heart. Proteomic analysis and gene expression profiling using qPCR were performed on the heart to achieve a comprehensive understanding. The marked reduction of the radical scavenger carnosine and the increased gene expression of catalase and Sestrin2 in the heart suggested elevated oxidative stress. A decrease in Complex I proteins and an increase in Complex I gene expression indicate rapid mitochondrial turnover in diabetic cardiomyocytes. Additionally, the increased expression of adenylate kinase and xanthine oxidoreductase accelerated the adenosine monophosphate degradation pathway, leading to reactive oxygen species generation. These insights into mitochondrial dysfunction and metabolic disturbances could inform the development of innovative therapies and pharmacological approaches for managing diabetic heart failure.
No takes yet. Share an insight, caveat, or question.
Tanabe et al. (2025) studied Diabetic cardiomyopathy (n=12). Zucker diabetic fatty (ZDF) rat model vs. Sprague Dawley (SD) rats was evaluated on Metabolic, lipidomic, and proteomic changes in the heart. In a type 2 diabetic rat model, impaired glycolysis and lipid metabolism led to compensatory ATP production through adenylate kinase, generating reactive oxygen species via xanthine oxidoreductase and exacerbating mitochondrial dysfunction.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: